Search
Citas y referencias (122)
Invitrogen™
Paclitaxel (Taxol Equivalent) - for use in research only
Invitrogen ofrece Paclitaxel para fines de investigación solo a una pureza de > 98 % por HPLC. Paclitaxel (anteriormente denominadoMás información
| Número de catálogo | Cantidad |
|---|---|
| P3456 | 5 mg |
Número de catálogo P3456
Precio (MXN)
-
Cantidad:
5 mg
Invitrogen ofrece Paclitaxel para fines de investigación solo a una pureza de > 98 % por HPLC. Paclitaxel (anteriormente denominado taxol en algunas publicaciones científicas) es el nombre genérico aprobado para el fármaco contra el cáncer Taxol (marca registrada de Bristol-Myers Squibb Co). El Paclitaxel promueve el ensamblaje de la tubulina, produciendo agregados que no pueden ser despolimerizados por dilución, iones de calcio, frío o una serie de fármacos que alteran los microtúbulos. Las células cultivadas tratadas con Paclitaxel se bloquean en las fases G2 y M del ciclo celular.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
FormularioLiofilizado
InhibidoresInhibidor citoesquelético
Cantidad5 mg
Condiciones de envíoTemperatura ambiente
Inhibición o diana específicaTubulina
Tipo de productoPaclitaxel
Unit SizeEach
Contenido y almacenamiento
Almacenar en congelador entre -5 °C y -30 °C
Citations & References (122)
Citations & References
Abstract
A phase II study of taxol in patients with malignant melanoma.
Journal:Invest New Drugs
PubMed ID:1673965
Based on results of a phase I study demonstrating antitumor activity of taxol in patients with melanoma, 34 patients with documented metastatic melanoma received taxol, 250 mg/m2, as a 24-hours infusion, repeated every 21 days, in this phase II study. All patients received premedication with dexamethasone, diphenhydramine and cimetidine. Four
Regulation of melanosome movement in the cell cycle by reversible association with myosin V.
Journal:J Cell Biol
PubMed ID:10491390
'Previously, we have shown that melanosomes of Xenopus laevis melanophores are transported along both microtubules and actin filaments in a coordinated manner, and that myosin V is bound to purified melanosomes (Rogers, S., and V.I. Gelfand. 1998. Curr. Biol. 8:161-164). In the present study, we have demonstrated that myosin V
Chemical subdomains within the kinetochore domain of isolated CHO mitotic chromosomes.
Journal:J Cell Biol
PubMed ID:1830054
'We have used indirect immunofluorescence in combination with correlative EM to subdivide the mammalian kinetochore into two domains based on the localization of specific antigens. We demonstrate here that the fibrous corona on the distal face of the kinetochore plate contains tubulin (previously shown by Mitchison, T. J., and M.
Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria.
Journal:Cell
PubMed ID:9657148
'Mouse kif5B gene was disrupted by homologous recombination. kif5B-/- mice were embryonic lethal with a severe growth retardation at 9.5-11.5 days postcoitum. To analyze the significance of this conventional kinesin heavy chain in organelle transport, we studied the distribution of major organelles in the extraembryonic cells. The null mutant cells
Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules.
Journal:J Biol Chem
PubMed ID:10713100
'The Wiskott-Aldrich syndrome is an inherited X-linked immunodeficiency characterized by thrombocytopenia, eczema, and a tendency toward lymphoid malignancy. Lymphocytes from affected individuals have cytoskeletal abnormalities, and monocytes show impaired motility. The Wiskott-Aldrich syndrome protein (WASP) is a multi-domain protein involved in cytoskeletal organization. In a two-hybrid screen, we identified the